Showing 1261-1270 of 9076 results for "".
Increased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/series/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arouDermwireTV: Pharma Partnership Boosts Spesolimab, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-pharma-partnership-boosts-spesolimab-plus-more/36519/In this episode of Dermwire TV, two pharma leaders partner to commercialize SPEVIGO for patients with generalized pustular psoriasis; interest in red light devices is up; and experts take a look at what’s new in psoriasis treatments on the Practical Dermatology Podcast.AI for Patient Education and More
https://practicaldermatology.com/series/c-suite-chats/ai-for-patient-education-and-more/36239/Anastasia Georgievskaya, founder of Haut.AI, discusses the impact of new artificial intelligence tools such as a virtual skincare try-on that shows customers how sunscreen and its ingredients will impact skin over time.2015 Cosmetic Surgery Forum: Jeanine Downie, MD
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/2015-cosmetic-surgery-forum-jeanine-downie-md/18264/Rafael Nunes, MD on LightSheer Duet and AcuPulse
https://practicaldermatology.com/topics/general-topics/rafael-nunes-md-on-lightsheer-duet-and-acupulse/19284/Teledermatology Update: Restrictions Lifted Due to COVID-19
https://practicaldermatology.com/topics/practice-management/teledermatology-update-restrictions-lifted-due-to-covid-19/23256/Easing of guidelines may allow more practices to add teleconsults.The Excoriated and Bleeding Edge: Updates in Eczema for the Clinician
https://practicaldermatology.com/topics/general-topics/the-excoriated-and-bleeding-edge-updates-in-eczema-for-the-clinician/21469/Atopic dermatitis continues to present treatment challenges, but a steady juggling of four main components—moisturization, antibiotics, anti-inflammatory, and antipruritics— help to maximize control of the disease.The Eyes Have It
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-eyes-have-it-1/23798/New and unique treatments for the eyelid area are having a momentBimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.How Epidermolysis Bullosa Treatments Went from Blisters to Breakthroughs
https://practicaldermatology.com/topics/rare-disease/how-epidermolysis-bullosa-treatments-went-from-blisters-to-breakthroughs/54391/Current FDA-approved therapies oleogel-S10, beremagene geperpavec, and prademagene zamikeracel represent major therapeutic breakthroughs for the treatment of epidermolysis bullosa (EB). Earlier systemic intervention, improved nutrition, and proactive management of complications have extended surviv